Previous 10 | Next 10 |
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FB-401 for the treatment of atopic dermatitis. FB-401 is a topically ...
Forte Biosciences ([[FBRX]] -4.4%) has dosed the first patient in its Phase 2 study, evaluating FB-401 for the treatment of atopic dermatitis, also known eczema is a condition that make skin red and itchy.The study will enroll 124 patients aged 2 years and older, with primary endpoint of...
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the clinical trial of FB-401 for the treatment of atopic dermatitis. The multi-center, placebo controlled clinical ...
AstraZeneca announces encouraging results from OSTRO trial AstraZeneca ( AZN ) reported positive data from its Phase III OSTRO trial pertaining Fasenra. The study met both its co-primary endpoints in patients with chronic rhinosinusitis with nasal polyps. The safety profile and tolerabil...
Forte Biosciences (NASDAQ: FBRX ) announces full results of Phase 1/2a trial of lead product candidate, FB-401 in atopic dermatitis (AD) patients in Science Translational Medicine. More news on: Forte Biosciences, Inc., Healthcare stocks news, Read more ...
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the publication in Science Translational Medicine of the full results of the Phase 1/2a data for its lead product candidate, FB-401. FB-401, a live biotherapeutic con...
Brookline's has initiated coverage on Forte Biosciences ( FBRX +13.9% ) with a Buy rating and a price target of $90 (~200% upside). Sees a favorable risk-reward for its lead asset FB-401 in inflammatory skin diseases. More news on: Forte Biosciences, Inc., Healthcare stocks news, ...
Shares of Forte Biosciences ( FBRX +13.4% ) are trading higher on after Truist's analyst Nicole Germino has initiated coverage of the company's stock with a "Buy" recommendation and set a price target of $70 per share (150% upside). More news on: Forte Biosciences, Inc., Healthcare stock...
Forte Biosciences, Inc. (NASDAQ: FBRX) ( www.fortebiorx.com ), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee...
Forte Biosciences (NASDAQ: FBRX ) : Q2 GAAP EPS of -$9.52. More news on: Forte Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Forte Biosciences Inc. Company Name:
FBRX Stock Symbol:
NASDAQ Market:
Forte Biosciences Inc. Website:
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlights ȁ...
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 Business Highlights “Forte achieved a major...